Cover Image
市場調查報告書

OpportunityAnalyzer:全球的痛風市場--市場機會的分析和未來預測

OpportunityAnalyzer: Gout - Opportunity Analysis and Forecast to 2018

出版商 GlobalData 商品編碼 302705
出版日期 內容資訊 英文 181 Pages
訂單完成後即時交付
價格
Back to Top
OpportunityAnalyzer:全球的痛風市場--市場機會的分析和未來預測 OpportunityAnalyzer: Gout - Opportunity Analysis and Forecast to 2018
出版日期: 2014年04月30日 內容資訊: 英文 181 Pages
簡介

全球的主要6國之痛風市場、2013年達到9億8900萬美金的規模。今後(2018年為止)的年平均成長率(CAGR)由各部門分析如下、急性痛風治療藥的狀況為15%、慢性痛風治療藥(消炎藥、降尿酸藥等)的狀況為18.8%。另外、2018年的急性痛風治療藥的市場規模為3億3700萬美金、慢性痛風治療藥為19億美金、預計會是目前的一倍大。目前對於痛風的標準治療水準也相當的高、此外因治療費用便宜之故、市場呈現成功的狀態因此屏障相當的高。今後市場的主要促進因素為、目前的治療技術中較難應對的難治性痛風的相關研究開發(R&D)的促進、及未滿足的需求。

本報告書內容為、痛風的治療法之研究、開發的最新趨勢調查和、相關市場的未來預測與實施、疾病的概要及現階段的治療法、尚未被滿足的需求、市場機會的評價、今後5年間的併發件數之預測值、臨床試驗的進行狀況、新治療藥的開發中評價、今後的市場趨勢等調查。

第1章 目次

第2章 介紹

第3章 疾病的概要

  • 病因和病態
    • 病因
    • 病態生理
  • 症狀
  • 風險因素
  • 預測
  • QoL(生活的品質)

第4章 免疫學

  • 風險因素和共存症
  • 全球的趨勢
    • 美國
    • 歐洲主要5國
  • 預測方法
    • 使用的資料來源
    • 沒有使用的資料來源
    • 預測的前提條件和方法
  • 痛風的免疫學預測(今後11年間分)
    • 診斷的發病件數
    • 接受診斷的發病者數
  • 議論
    • 免疫學傾向的相關考察
    • 分析的界線
    • 分析的強勢

第5章 現在的治療附加條件

  • 概要
  • 產品介紹
    • 消炎藥
    • 降尿酸藥

第6章 尚未被滿足的需求之評價和機會分析

  • 概要
  • 痛風的醫師□患者的認識
    • 尚未被滿足的需求
    • 差異的分析
    • 市場機會
  • 痛風治療時的違反規則
  • 更早、更正確的痛風診斷
  • 針對難治性痛風治療、有效果及安全的治療法

第7章 研究開發(R&D)策略

  • 概要
    • 難治性痛風患者用治療藥:附加療法的新尿酸排泄促進藥
    • 難治性痛風患者的治療藥:PEG化尿酸
    • 白細胞介素-1β傳達路徑的抑制性藥物之小分子
    • 企業收買□許可
  • 臨床實驗的設計
    • 現在的臨床試驗設計
    • 未來的臨床試驗設計

第8章 生產線分析

  • 概要
  • 臨床實驗中有希望的藥劑
    • Lesinurad (RDEA-594)
    • Ulodesine (BCX4208)
  • 初期階段的創新途徑

第8章 生產線評價的分析

  • 主要的生產線藥劑之臨床面的基準
  • 主要生產線藥劑的商業面基準
  • 競爭力的評價
  • 今後5年間的銷售額預測
    • 美國
    • 歐洲主要5國

第10章 附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDHC020POA

GlobalData estimates the 2013 sales for gout at approximately $989m across the 6MM covered in this report. The acute gout segment of the market will double in size over the forecast period, reaching $337m in 2018 at a CAGR of 15%. The chronic gout market, which encompasses urate-lowering and prophylactic anti-inflammatory therapies, will experience even faster growth at a CAGR of 18.8%, and it will more than double in size, reaching over 1.9 billion in 2018. With the current standard of care for gout already encompassing very successful and cheap treatments, the bar for success in the gout market is quite high. As a result, companies are shifting the focus of their research toward more severe gout cases, trying to address the greatest unmet needs. One of the major drivers of the gout market is the growing number of patients suffering from difficult-to-treat gout, for whom the standard therapies are inappropriate due to the presence of comorbidities, unresponsiveness, or intolerance. Targeting this patient niche is the strongest trend in the research and development (R&D) strategies of the gout players.

Highlights

Key Questions Answered

  • Although the standard treatments are cheap and effective in most gout patients, there are a growing number of patients for whom the standard therapies are inappropriate. Gout market is still marked by the presence of a number of unmet needs in current treatments. What are the main unmet needs in this market? Will the drugs under development fulfil the unmet needs of the gout market?
  • The late-stage gout pipeline is sparsely populated; however these drugs in development will be a strong driver of the gout market growth. Which of these drugs will attain high sales revenues during 2013-2018? Which of these drugs will have the highest peak sales at the highest CAGR, and why?
  • The more aggressive approach to urate-lowering treatment will increase the patient pool treated with urate-lowering agents and prophylactic anti-inflammatory therapies. How will these changes impact the growth of the future market?

Key Findings

  • One of the main drivers of the enormous expansion of the gout market will be the introduction of the novel urate-lowering agents, lesinurad and ulodesine, which will be used as add-on therapies to the current standard of care and target the treatment-failure gout population.
  • Another strong driver will be the more aggressive approach to urate-lowering treatment, as recommended by the latest treatment guidelines, which will increase the patient pool treated with urate-lowering agents and prophylactic anti-inflammatory therapy.
  • Companies are shifting the focus of their research toward more severe gout cases, trying to address the greatest unmet needs.
  • Reasons for inadequate gout treatment include a poor patient understanding of their disease and physician failure to develop targeted treatment plans.

Scope

  • Overview of gout, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
  • Annualized gout therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2013 and forecast for five years to 2018.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the gout therapeutics market.
  • Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
  • Analysis of the current and future market competition in the global gout therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Additionally a list of acquisition targets included in the pipeline product company list.
  • Develop business strategies by understanding the trends shaping and driving the gout therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the gout therapeutics market in future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Track drug sales in the 6MM gout therapeutics market from 2013-2018.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Etiology
    • 3.1.2. Pathophysiology
  • 3.2. Symptoms
  • 3.3. Risk Factors
  • 3.4. Prognosis
  • 3.5. Quality of Life

4. Epidemiology

  • 4.1. Risk Factors and Comorbidities
  • 4.2. Global Trends
    • 4.2.1. US
    • 4.2.2. 5EU
  • 4.3. Forecast Methodology
    • 4.3.1. Sources Used
    • 4.3.2. Sources Not Used
    • 4.3.3. Forecast Assumptions and Methods
  • 4.4. Epidemiological Forecast for Gout (2013-2023)
    • 4.4.1. Diagnosed Incidence
    • 4.4.2. Diagnosed Prevalence
  • 4.5. Discussion
    • 4.5.1. Epidemiological Forecast Insight
    • 4.5.2. Limitations of the Analysis
    • 4.5.3. Strengths of the Analysis

5. Current Treatment Options

  • 5.1. Overview
  • 5.2. Product Profiles
    • 5.2.1. Anti-Inflammatory Therapies
    • 5.2.2. Urate-Lowering Therapies

6. Unmet Needs Assessment and Oppportunity Analysis

  • 6.1. Overview
  • 6.2. Physician and Patient Awareness of Gout
    • 6.2.1. Unmet Needs
    • 6.2.2. Gap Analysis
    • 6.2.3. Opportunity
  • 6.3. Noncompliance to Gout Therapies
    • 6.3.1. Unmet Needs
    • 6.3.2. Gap Analysis
    • 6.3.3. Opportunity
  • 6.4. Earlier and More Accurate Diagnosis of Gout
    • 6.4.1. Unmet Needs
    • 6.4.2. Gap Analysis and Opportunity
    • 6.4.3. Opportunity
  • 6.5. Efficacious and Safe Treatment of Difficult-to-Treat Gout
    • 6.5.1. Unmet Needs
    • 6.5.2. Gap Analysis and Opportunity
    • 6.5.3. Opportunity

7. Research and Development Strategies

  • 7.1. Overview
    • 7.1.1. Targeting Patients with Refractory Gout - Novel Uricosuric Drugs as Add-On Therapy
    • 7.1.2. Targeting Patients with Refractory Gout - PEGylation of Uricase
    • 7.1.3. Small Molecules as Inhibitors of the Interleukin-1. Beta Pathway
    • 7.1.4. Acquisitions and Licensing
  • 7.2. Clinical Trial Design
    • 7.2.1. Current Clinical Trial Design
    • 7.2.2. Future Clinical Trial Designs

8. Pipeline Assessment

  • 8.1. Overview
  • 8.2. Promising Drugs in Clinical Development
    • 8.2.1. Lesinurad (RDEA-594)
    • 8.2.2. Ulodesine (BCX4208)
  • 8.3. Innovative Early-Stage Approaches

9. Pipeline Valuation Analysis

  • 9.1. Clinical Benchmark of Key Pipeline Drugs
  • 9.2. Commercial Benchmark of Key Pipeline Drugs
  • 9.3. Competitive Assessment
  • 9.4. Top-Line Five-Year Forecast
    • 9.4.1. US
    • 9.4.2. 5EU

10. Appendix

  • 10.1. Bibliography
  • 10.2. Abbreviations
  • 10.3. Methodology
  • 10.4. Forecasting Methodology
    • 10.4.1. Diagnosed Gout Patients
    • 10.4.2. Percent Drug-Treated Patients
    • 10.4.3. Drugs Included in Each Therapeutic Class
    • 10.4.4. Launch and Patent Expiry Dates
    • 10.4.5. General Pricing Assumptions
    • 10.4.6. Individual Drug Assumptions
    • 10.4.7. Pricing of Pipeline Agents
  • 10.5. Physicians and Specialists Included in this Study
  • 10.6. About the Authors
    • 10.6.1. Analyst
    • 10.6.2. Therapy Director - CVMD and Infectious Disease
    • 10.6.3. Epidemiologist
    • 10.6.4. Global Head of Healthcare
  • 10.7. About GlobalData
  • 10.8. Disclaimer

List of Tables

  • Table 1: Risk Factors and Comorbidities for Gout
  • Table 2: Summary of Reported Incidence and Prevalence of Gout in the 6MM*
  • Table 3: American College of Rheumatology Criteria for the Clinical Diagnosis of Gout
  • Table 4: Sources of Gout Incidence Data in 6MM
  • Table 5: Sources of Gout Prevalence Data in 6MM
  • Table 6: Sources of Gout Flare and Tophaceous Gout Data in 6MM
  • Table 7: 6MM, Sources Not Used in the Epidemiological Analysis of Gout
  • Table 8: 6MM, Diagnosed Incident Cases of Gout, Both Sexes, Ages ≥20 Years, N, 2013-2023
  • Table 9: 6MM, Age-Specific Diagnosed Incident Cases of Gout, Both Sexes, N (Row %), 2013
  • Table 10: 6MM, Sex-Specific Diagnosed Incident Cases of Gout, Ages ≥20 Years, N (Row %), 2013
  • Table 11: 6MM, Diagnosed Prevalent Cases of Gout, Both Sexes, Ages ≥20 Years, N, 2013-2023
  • Table 12: 6MM, Age-Specific Diagnosed Prevalent Cases of Gout, Both Sexes, N (Row %), 2013
  • Table 13: 6MM, Sex-Specific Diagnosed Prevalent Cases of Gout, Ages ≥20 Years, N (Row %), 2013
  • Table 14: Leading Branded Treatments for Gout
  • Table 15: Nonsteroidal Anti-Inflammatory Drugs SWOT Analysis, 2013
  • Table 16: Product Profile - Colcrys
  • Table 17: Colcrys SWOT Analysis, 2013
  • Table 18: Glucocorticoids SWOT Analysis, 2013
  • Table 19: Product Profile - Ilaris
  • Table 20: Ilaris SWOT Analysis, 2013
  • Table 21: Product Profile - Kineret
  • Table 22: Kineret SWOT Analysis, 2013
  • Table 23: Product Profile - Allopurinol
  • Table 24: Allopurinol SWOT Analysis, 2013
  • Table 25: Product Profile - Uloric
  • Table 26: Uloric SWOT Analysis, 2013
  • Table 27: Uricosuric drugs SWOT Analysis, 2013
  • Table 28: Product Profile - Krystexxa
  • Table 29: Krystexxa SWOT Analysis, 2013
  • Table 30: Unmet Need and Opportunity in Gout
  • Table 31: Examples of Pivotal RCTs of Approved Treatments for Acute Gout
  • Table 32: Examples of Pivotal RCTs of Approved Treatments for Chronic Gout
  • Table 33: Gout - Late Stage Pipeline, 2012
  • Table 34: Product Profile - Lesinurad
  • Table 35: Lesinurad SWOT Analysis, 2013
  • Table 36: Product Profile - Ulodesine
  • Table 37: Ulodesine SWOT Analysis, 2013
  • Table 38: Early-Stage Pipeline Products in Gout
  • Table 39: Clinical Benchmark of Key Pipeline Drugs - Anti-Inflammatory Therapies
  • Table 40: Clinical Benchmark of Key Pipeline Drugs - Urate-Lowering Therapies
  • Table 41: Commercial Benchmark of Key Pipeline Drugs - Anti-Inflammatory Therapies
  • Table 42: Commercial Benchmark of Key Pipeline Drugs - Urate-Lowering Therapies
  • Table 43: Top Line Sales Forecasts ($m) for Gout, 2013-2018
  • Table 44: Key Events Impacting Sales for Gout, 2013-2018
  • Table 45: Gout Market - Drivers and Barriers, 2013-2018
  • Table 46: Key Launch Dates
  • Table 47: Key Patent Expiries

List of Figures

  • Figure 1: Overview of Purine Metabolism, Leading to Uric Acid Formation
  • Figure 2: Stages of Gout
  • Figure 3: 6MM, Diagnosed Incident Cases of Gout, Both Sexes, Ages ≥20 Years, N, 2013-2023
  • Figure 4: 6MM, Age-Specific Diagnosed Incident Cases of Gout, Both Sexes, N, 2013
  • Figure 5: 6MM, Sex-Specific Diagnosed Incident Cases of Gout, Ages ≥20 Years, N, 2013
  • Figure 6: 6MM, Age-Standardized Diagnosed Incidence of Gout (Cases per 100,000 Population), Ages ≥20 Years, by Sex, 2013
  • Figure 7: 6MM, Diagnosed Prevalent Cases of Gout, Both Sexes, Ages ≥20 Years, N, 2013-2023
  • Figure 8: 6MM, Age-Specific Diagnosed Prevalent Cases of Gout, Both Sexes, N, 2013
  • Figure 9: 6MM, Sex-Specific Diagnosed Prevalent Cases of Gout, Ages ≥20 Years, N, 2013
  • Figure 10: 6MM, Age-Standardized Diagnosed Prevalence (%) of Gout, Ages ≥20 Years, by Sex, 2013
  • Figure 11: 6MM, Number of Gout Flares in the Diagnosed Prevalent Population of Gout, Both Sexes, Ages ≥20 Years, N, 2013 and 2023
  • Figure 12: 6MM, Tophaceous Gout Cases in the Diagnosed Prevalent Population of Gout, Both Sexes, Ages ≥20 Years, N, 2013 and 2023
  • Figure 13: Mechanisms Targeted by Marketed and Late-Stage Pipeline Drugs
  • Figure 14: Competitive Assessment of the Novel Anti-Inflammatory Agent for Gout, 2013-2018
  • Figure 15: Competitive Assessment of the Late-Stage Pipeline Urate-Lowering Agents for Gout, 2013-2018
  • Figure 16: Sales for the Gout Market, US and 5EU (2013-2018)
Back to Top